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Abstract
Background: This study assesses whether comparatively high prostate cancer incidence rates
among white men in Utah represent higher rates among members of the Church of Jesus Christ of
Latter-day Saints (LDS or Mormons), who comprise about 70% of the state's male population, and
considers the potential influence screening has on these rates.
Methods: Analyses are based on 14,693 histologically confirmed invasive prostate cancer cases
among men aged 50 years and older identified through the Utah Cancer Registry between 1985
and 1999. Cancer records were linked to LDS Church membership records to determine LDS
status. Poisson regression was used to derive rate ratios of LDS to nonLDS prostate cancer
incidence, adjusted for age, disease stage, calendar time, and incidental detection.
Results: LDS men had a 31% (95% confidence interval, 26% – 36%) higher incidence rate of
prostate cancer than nonLDS men during the study period. Rates were consistently higher among
LDS men over time (118% in 1985–88, 20% in 1989–92, 15% in 1993–1996, and 13% in 1997–99);
age (13% in ages 50–59, 48% in ages 60–69, 28% in ages 70–79, and 16% in ages 80 and older); and
stage (36% in local/regional and 17% in unstaged). An age- and stage-shift was observed for both
LDS and nonLDS men, although more pronounced among LDS men.
Conclusions: Comparatively high prostate cancer incidence rates among LDS men in Utah are
explained, at least in part, by more aggressive screening among these men.
Background
Among the 11 cancer registries that contract with the Sur-
veillance, Epidemiology, and End Results (SEER) Program
of the US National Cancer Institute, the Utah Cancer Reg-
istry reports the lowest overall incidence of cancer. During
the years 1995–1999, age-adjusted (to the 2000 US popu-
lation) invasive cancer incidence rates in white men for
the leading 10 sites, per 100,000 person-years, were 393.1
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in Utah compared with 451.0 in SEER (without Utah) [1].
Lower rates in Utah were observed for all sites except pros-
tate cancer and melanoma of the skin (174.5 vs. 157.8 for
prostate, 42.7 vs. 81.9 for lung and bronchus, 48.8 vs.
63.9 for colon and rectum, 31.7 vs. 38.8 for urinary blad-
der, 22.4 vs. 24.6 for non-Hodgkin's lymphoma, 25.3 vs.
23.4 for melanoma of the skin, 13.0 vs. 16.3 for oral cavity
and pharynx, 11.0 vs. 15.5 for kidney and renal pelvis,
13.9 vs. 16.7 for leukemia, and 9.9 vs. 12.2 for pancreas).
Comparatively high prostate cancer incidence rates in the
1990s among white men in Utah have been reported pre-
viously [2,3].
In 1847, members of the Church of Jesus Christ of Latter-
day Saints (LDS or Mormon) settled the Salt Lake Valley
in northern Utah [4]. Over the next several years, LDS
Church members settled over 350 communities through-
out the territory. Today, about 70% of Utah's 2.2 million
population is affiliated with the LDS Church [5,6]. Over
85% of the state's population is white, non-Hispanic [6].
Low cigarette-smoking and alcohol-drinking prevalence
observed among LDS helps explain the comparatively low
rates for many of these cancer sites in Utah [5]. Whether
the high prostate cancer incidence rates reflect higher rates
among LDS is unclear.
We linked electronic records from the LDS Church mem-
bership files and the Utah Cancer Registry to examine the
magnitude and temporal trends in prostate cancer inci-
dence rates among LDS and nonLDS residents of Utah for
the calendar years 1985 through 1999. Cases judged to
have been incidentally detected through transurethral re-
section of the prostate (TURP), a procedure typically used
to treat obstructive uropathy, were also identified and
considered in the rate calculations to provide a clearer in-
dication of the effect of screening on the incidence rates of
prostate cancer. We also examined results from a
statewide health survey to characterize prostate-specific
antigen screening patterns by religious affiliation.
Methods
We combined information from LDS Church member-
ship records and the population-based Utah Cancer Reg-
istry to calculate prostate cancer incidence rates for LDS
and nonLDS populations in Utah during the period
1985–99. We also examined results from a statewide
health survey to characterize PSA screening patterns in
these two groups.
Utah Cancer Registry
The population-based Utah Cancer Registry (UCR) was
established in 1966 and has continuously participated in
the National Cancer Institute's Surveillance, Epidemiolo-
gy, and End Results (SEER) program since 1973. UCR staff
members and local cancer registrars identify incident cases
of cancer among Utah residents through routine and sys-
tematic review of pathology reports, medical records, radi-
ation therapy records, hospital discharge lists, and vital
records. Tumor characteristics including histology, grade,
and primary site are coded according to the International
Classification of Disease for Oncology-Second Edition
(ICDO-2) [7]. Categories of stage of disease at diagnosis
are documented in the Summary Staging Guide of the
SEER program of the National Cancer Institute [8]. Regis-
try records also include information regarding treatment
and patient characteristics such as age at diagnosis, gen-
der, race/ethnicity, and place of residence at diagnosis. In-
formation regarding patient characteristics, cancer
diagnosis, and treatment is ascertained from specific state-
ments in medical records, reports from private pathology
laboratories and radiotherapy units, and death certifi-
cates. Cancer surveillance in Utah is conducted in accord-
ance with standards instituted by the SEER program and
the North American Association of Central Cancer Regis-
tries [9,10].
Linkage of cancer data with LDS church records
UCR records were linked to LDS Church membership
records to determine membership in the LDS Church. The
linkage process took place under direct supervision of the
Church and the UCR and was conducted in the Church's
Member and Statistical Records Department. Confidenti-
ality of record information was strictly enforced. After the
records were linked, all personal identifying information
was stripped from the database.
Records were linked using the probabilistic linking pro-
gram LinkPro [11]. The program calculates probabilities
to identify whether a pair of records refers to the same per-
son. Ten variables that were common to both sets of
records were used to link the records: first, middle, and
last names; birth day; birth month; birth year; gender; zip
code; vital status; and maiden name. SOUNDEX versions
of the names were used in the matching process, while ac-
tual names were used in the review process.
There were 121,967 incident cases of cancer identified in
the UCR database from 1973 to 2000 and approximately
6.6 million records in the LDS Church database. Records
were linked in three stages. The first stage linked all
records that matched exactly on first, middle, and last
names; complete birth date; and gender. There were
36,187 such records declared matches without review.
The second stage consisted of taking the remaining
records and forcing them to link on last name and at least
five additional variables. The 6,652 records that linked on
eight additional variables were declared matches without
review. Of the 18,587 records that linked on seven addi-
tional variables, 17,612 were declared matches without
review, and 975 were reviewed with 859 declaredBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/14
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matches. Of the 21,146 records that linked on six addi-
tional variables, 14,378 were declared matches without
review, and 6,768 were reviewed of which 2,812 were de-
clared matches. Finally, of the 22,492 records that
matched on five additional variables, 1,650 were declared
matches without review, 5,629 were reviewed with 1,328
declared matches, and 15,213 were declared non-matches
without review. The third stage of the linkage process con-
sisted of taking the remaining unlinked records and forc-
ing them to link on first name and at least six other
additional variables. There were 3,338 such records. All
were reviewed, with 380 declared matches. These stages
resulted in 81,617 (68%) of the UCR records being linked
to a Church record.
Data
All incident cases of prostate cancer (ICDO-2 site code
C61.9) that were diagnosed among Utah residents during
the time period 1985–99 were identified from records of
the Utah Cancer Registry. Lymphomas of the prostate (IC-
DO-2 histologies 9590–9989) were excluded from the
study. Analyses were further restricted to histologically
confirmed cases that were 50 years and older at the time
of prostate cancer diagnosis. Stage categories of disease at
diagnosis were local/regional, distant, and unstaged. Lo-
cal and regional stages were combined because of the
large proportion of cases upsataged because of surgery
[12].
TURP and Incidental Detection
Although the UCR has historically collected surgery infor-
mation on cancer cases, including whether a prostate can-
cer case underwent a TURP, not until 1998 did they
identify whether the TURP led to or was the result of a
prostate cancer diagnosis. This change in the level of infor-
mation collected was made among all the registries partic-
ipating in the SEER program. In the UCR during 1998–99,
the proportion of TURPs performed among cases resulting
in an incidental finding because of the surgery for benign
disease was 0.6786. The log of the odds in favor of this
event was then regressed on age using logistic regression.
Age was not statistically significant (i.e., Chi-square =
1.0237, p = 0.3116). Age and age-squared terms were also
fit in the model, but neither was statistically significant.
Because the proportion of incidental detection among
cases undergoing a TURP was not associated with age, we
multiplied in each age category for each year 1985
through 1997 the proportion 0.6786 by the total number
of age- and year-specific TURPs recorded among cases to
get an estimate of the number of TURPs that led to a pros-
tate cancer diagnosis.
1996 Utah Health Status Survey
The 1996 Utah Health Status Survey is a cross-sectional
random survey sponsored by the Utah Department of
Health. The Gallup Organization collected the data by in-
corporating a telephone survey instrument into a compu-
ter-assisted, random-digit-dialing software program called
SURVENT. Supervised interviews were conducted across
twelve local health districts in Utah by trained interview-
ers. Although the survey questionnaire covered several
topics, we only used data from questions on PSA screen-
ing and religious status. The interview process occurred
during June 1 through August 31, 1996. Interviews were
conducted with one randomly selected adult aged 18
years or older in each household. If required, as many as
nine telephone attempts were made to contact a selected
household. The response rate was 66.3%. In order to more
accurately generalize the survey results to the Utah popu-
lation, post-survey weighting adjustments were made. Ad-
justments weighted the sample to be proportionally
consistent with age, sex, geographic, and Hispanic status
distributions of the 1996 Utah population.
Statistical analysis
Age-adjusted prostate cancer incidence rates were calculat-
ed for individual calendar years and for the following year
groups: 1985–88, 1989–92, 1993–96, and 1997–99.
These rates were calculated by the direct method with the
United States standard population for the year 2000 [13].
Rates were calculated for both LDS and nonLDS popula-
tions in Utah and are expressed per 100,000 person-years.
The Member and Statistical Records Department of the
LDS Church provided annual age- and sex-specific esti-
mates of the number of LDS Church members in Utah
(Larry Elkington, Manager of Church Management Infor-
mation Center, personal communication). Estimates for
the nonLDS population of Utah were derived by subtract-
ing the number of LDS Church members from the Utah
population provided by the US Bureau of the Census [14].
Poisson regression was used to estimate the incidence rate
ratio between LDS and nonLDS [15]. Appropriate models
reported below were selected based on the deviance good-
ness-of-fit test. Analyses were performed with standard
packages of the Statistical Analysis System (SAS) [16].
Results
A total of 14,693 incident cases of histologically con-
firmed invasive prostate cancer in men aged 50 years and
older were diagnosed among Utah residents during the
period 1985–99. Based on linkage with LDS Church
records, 11,291 (76.8%) of these cases were determined
to be LDS Church members. There were 12,088 (82.3%)
with local/regional stage, 1,009 (6.9%) with distant stage,
and 1,594 (10.8%) with unstaged prostate cancer. Two
cases had missing stage information.
The frequency of cases is presented according to religious
preference, calendar year, and age in Table 1. For both
LDS and nonLDS, a shift occurred over time from casesBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/14
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being diagnosed at older ages to younger ages. For the first
three time periods, LDS compared with nonLDS cases
were less likely to be diagnosed in their 50 s and more
likely to be diagnosed in their 80 s. The frequency of cases
is also presented according to religious preference, calen-
dar year, and stage (Table 2). A noticeable stage shift oc-
curred from distant to local/regional disease over time for
both LDS and nonLDS cases. Only in the years 1989
through 1992 do LDS cases have a significantly higher
percentage diagnosed with local/regional disease.
Local/regional-staged TURP- and nonTURP-detected age-
adjusted prostate cancer incidence rates for men 50 years
of age and older in Utah are presented according to reli-
gious preference and calendar year (Figure 1). NonTURP-
detected prostate cancer incidence rates are generally
higher for LDS men across the years, particularly during
the PSA-induced peak. Despite this observation, TURP-de-
tected prostate cancer incidence rates are similar. Distant-
staged age-adjusted prostate cancer incidence rates for
men 50 years of age and older in Utah are also presented
by religious preference and calendar year (Figure 2). These
rates are generally similar.
A Poisson regression model, adjusted for age and stage at
diagnosis, calendar time, and whether prostate cancer was
TURP- or nonTURP-detected, indicated that LDS com-
pared with nonLDS have 1.31 (95% confidence interval,
1.26 – 1.36) times the incidence rate of prostate cancer
among men aged 50 years and older in Utah. The adjusted
Poisson regression model gave rate ratios of LDS to
nonLDS of 2.18 (1.99 – 2.40) in 1985–88, 1.20 (1.12 –
1.29) in 1989–92, 1.15 (1.08 – 1.24) in 1993–1996, and
1.13 (1.04 – 1.22) in 1997–99. Adjusted rate ratios also
indicated significantly higher rates for LDS compared with
nonLDS for each age group [1.13 (1.01–1.27) in ages 50–
59, 1.48 (1.38–1.58) in ages 60–69, 1.28 (1.21–1.36) in
ages 70–79, and 1.16 (1.04–1.28) in ages 80 and older]
and for certain stage categories [1.36 (1.31–1.43) in local/
regional stage, 0.97 (0.84–1.11) in distant stage, and 1.17
(1.04–1.31) in unstaged].
Table 1: Frequency of invasive prostate cancer cases diagnosed in Utah among men aged 50 years and older according to religious 
preference (LDS vs. nonLDS), calendar year, and age
1985–88 1989–92 1993–96 1997–99
LDS NonLDS LDS NonLDS LDS NonLDS LDS NonLDS
A g e N o .%N o .%N o .%N o .%N o .%N o .%N o .%N o .%
50–59 124 6.0 45 8.0 250 7.4 81 8.5 332 10.4 144 14.0 357 13.5 123 14.3
60–69 636 30.9 197 34.9 1113 33.0 270 28.5 1198 37.3 373 36.2 974 36.7 309 36.0
70–79 918 44.7 229 40.6 1442 42.7 449 47.4 1235 38.5 395 38.3 996 37.6 324 37.7
80+ 378 18.4 93 16.5 570 16.9 148 15.6 444 13.8 119 11.5 324 12.2 103 12.0
Chi-square MH 
Trend Chi-
square
7.36, p = 0.0611 6.13, p = 
0.0128
10.29, p = 0.0162 0.09, p = 
0.7581
12.49, p = 0.0059 7.42, p = 
0.0064
0.48, p = 0.9229 0.12, p = 
0.7342
Table 2: Frequency of prostate cancer cases diagnosed in Utah among men aged 50 years and older according to religious preference 
(LDS vs. non LDS), calendar year, and summary stage
1985–88 1989–92 1993–96 1997–99
LDS NonLDS LDS NonLDS LDS NonLDS LDS NonLDS
A g e N o .%N o .%N o .%N o .%N o .%N o .%N o .%N o .%
Local/Regional 1475 71.7 389 69.0 2608 77.3 687 72.5 2671 83.2 863 83.7 2573 97.1 822 95.8
Distant 238 11.6 85 15.1 275 8.1 100 10.5 162 5.1 57 5.5 64 2.4 28 3.3
Unstaged 343 16.7 90 15.9 492 14.6 161 17.0 376 11.7 111 10.8 13 0.5 8 0.9
Chi-square 5.00, p = 0.0819 9.99, p = 0.0068 0.98, p = 0.6116 4.00, p = 0.1351BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/14
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Finally, on the basis of the 1996 Utah Health Status Sur-
vey, LDS men compared with nonLDS men were more
likely to have received a PSA screen in the previous year
(Table 3).
Discussion
Evidence that prostate cancer incidence rates are sensitive
to screening is well established [2,3,17–20]. Potosky et al.
examined the potential influence that adoption of tran-
srectal ultrasound (TRUS) and PSA testing had on increas-
ing prostate needle biopsy rates in the SEER areas from
1986 through 1991 [17]. Both TRUS and PSA testing rates,
initially near zero, increased to almost 2,000 and 20,000
per 100,000, respectively. Their study further showed a
correlation between increasing needle biopsy rates and
prostate cancer incidence rates. Legler et al. added to our
understanding of the role of PSA testing on prostate can-
cer incidence rates by showing that first time PSA testing
proportions, not the overall PSA proportion, track closely
with prostate cancer incidence rates [20]. In a comparison
of prostate cancer incidence rates among white men in
five of the SEER areas (Detroit, Utah, Seattle-Puget Sound,
Iowa, and Connecticut), Brawley showed that the rates
were highest in Seattle from 1986 through 1991, but then
highest in Utah from 1992 through 1994 [21]. In a
consistent manner, the proportion of men receiving a first
time PSA tended to be highest in Seattle in the earlier years
but highest in Utah in the later years [20]. Because 76.8%
of diagnosed prostate cancer cases in Utah during our
study period were in LDS men, we may assume that the
relatively high proportion of first time PSA tests in Utah
primarily reflects LDS men.
The results, based on Poisson regression, indicate that
LDS men compared with nonLDS men residing in Utah,
after adjusting for age and stage at diagnosis, calendar
time and TURP experienced significantly higher prostate
cancer incidence rates. Unfortunately, our broad stage cat-
Figure 1
Age-adjusted (to the 2000 US standard population) TURP- 
and nonTURP-detected local/regional staged prostate cancer 
incidence rates for men aged 50 years and older in Utah 
according to religious preference and year of diagnosis
Figure 2
Age-adjusted (to the 2000 US standard population) distant 
staged prostate cancer incidence rates for men aged 50 years 
and older in Utah according to religious preference and year 
of diagnosisBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/14
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egories limited our ability to adjust for this variable such
that differences in stage could still be explaining some of
the higher incidence among LDS men. Nevertheless, the
higher rates among LDS men could be because they more
readily adopted TRUS and digital rectal exams in the first
time period, prior to widespread PSA screening, and then
more readily adopted PSA screening but to a lesser degree.
Historically, physicians have used digital rectal examina-
tions in early detection efforts [22,23]. In general, digital
rectal examination has a 1–2% detection rate and the PSA
test, which is relatively easy to perform, has a 3% detec-
tion rate in men who are older than 50 years of age [24].
Screening is further implicated by the fact that the higher
rate ratios of LDS to nonLDS prostate cancer incidence
occur in local/regional stage cases. Age- and stage-shifts in
the data are also consistent with higher levels of screening
among LDS men. Unfortunately, there is little screening
data available to allow us to directly evaluate the role
screening plays in the higher prostate cancer incidence
rates observed among LDS men. Nevertheless, based on
the 1996 Utah Health Status Survey we showed that LDS
men compared with nonLDS men were more likely to
have received a PSA test in the past year, overall and with-
in age categories. Yet the order of PSA received, whether a
first or subsequent PSA test, is unknown. In addition, we
do not know whether higher PSA screening use among
LDS men remained higher prior to or after 1996.
Studies have shown that men undergoing PSA screening
are more likely to display an overall constellation of
health-promoting behavior, such as not smoking and
seeking health care regularly [25,26]. Smokers are less
likely to use medical services [27,28], with one study find-
ing that 76% of nonsmokers compared with 64% of
smokers receiving regular checkups [26]. Utah has
historically experienced the lowest smoking prevalence in
the United States [29]. Utah smoking prevalence is cur-
rently closest to the Healthy People 2010 goal for the nation
of 12% [30], with smoking prevalence in the year 2000 of
12.9% compared with the next lowest prevalence in Cali-
fornia of 17.2 and nationally of 23.2% [31]. This low
smoking prevalence is primarily explained by the over
70% LDS population who attend church weekly, among
which less than 1% are current smokers [5]. Men who are
married and who have medical insurance have the highest
levels of PSA use in Utah [25]. According to the 1996 Utah
Health Status Survey, 74.7% of LDS men and 58.9% of
nonLDS men in Utah were married, and 92.2% of LDS
men compared with 86.2% of nonLDS men were medical-
ly insured [32].
In a consistent manner, studies have found that men who
are generally healthier [26,33], married [34,35], and more
educated [35,36] are more likely to be diagnosed with
prostate cancer than men with different characteristics. Yet
these men also tend to experience better survival [35,37–
39], indicating that they are possibly being diagnosed at
earlier stages because of more aggressive screening. In ad-
dition to LDS having comparatively low smoking preva-
lence, a higher proportion who are married, and a higher
proportion who are medically insured, 95% of LDS men
compared with 89% of nonLDS men reported having at
least a high school education, according to the 1996
Health Status Survey [32].
In our study, adjusting for TURP-detected cases allowed us
to better assess the influence of screening on prostate can-
cer incidence trends. Frequent use of TURP for benign
prostatic hyperplasia in the 1970s and 1980s and the rap-
id introduction and widespread adoption of PSA screen-
ing beginning in the late 1980s, tapped an extensive pool
of latent and preclinical prostate disease [40,41]. Consist-
ent with another study, we found that in the mid 1980s up
to 50% or more of all prostate cancer cases were inciden-
tally detected through TURPs [41]. However, as medica-
tions with few side effects became available to treat benign
prostatic hypterplasia and PSA screening became widely
adopted, TURP-detected cases declined from their peak in
1987 through 1993 [41]. Our results showed a similar de-
cline in the TURP-detected prostate cancer incidence rates,
followed by a leveling off between 1994 and 1999, for
both LDS and nonLDS cases in Utah. We also found the
level of TURP-detected rates to be very similar between
LDS and nonLDS.
Table 3: Percentage of men aged 50 years and older receiving a PSA test in the past year according to LDS status and age
LDS Age Group
Status 50–59 60–69 70+* 50+
LDS 134/240 (55.8%) 151/212 (71.2%) 116/162 (71.6%) 401/614 (65.3%)
NonLDS 54/102 (52.9%) 37/59 (62.7%) 28/43 (65.1%) 119/204 (58.3%)
*Because of small numbers among nonLDS in the age group 80+, age groups 70–79 and 80+ were combined. Bold-typed represent significantly 
greater PSA testing among LDS compared with nonLDS, based on a one-sided hypothesis test and the 0.05 level of significance.BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/14
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Data are not available to identify whether TURP rates dif-
fered between LDS and nonLDS. However, if we assume
they were similar or even higher among LDS, and given
the similar TURP-detected prostate cancer incidence rates
observed, there is no reason to believe that prostate cancer
is more common in LDS men. Indeed, an older study
based on Utah data covering the years 1971 through 1985
found that the age-adjusted (to the 1970 US standard)
prostate cancer incidence rates per 100,000 person-years
were 76.3 for LDS compared with 109.1 for nonLDS [42].
One goal of screening is to identify the presence of disease
before it becomes clinically evident. If PSA-based screen-
ing achieved this goal, we would anticipate dramatic in-
creases in the number of cases diagnosed with early stage
prostate cancer. The available data did not allow us to
restrict our analyses to cases with just localized disease.
Results from previous studies have demonstrated that
choice of therapy for prostate cancer may influence subse-
quent determination of staging. Specifically, many pa-
tients that clinically appeared to have localized disease
were determined to have regional stage disease based on
pathological review of tissue that was obtained from rad-
ical prostatectomy [43,44]. Similar patients that did not
undergo aggressive surgical treatment would not have had
the opportunity for a comparable evaluation of stage; the
latter group of patients would have remained classified
with localized disease. Therefore, it was not possible in
these data to distinguish between cases with true localized
disease and those who received a clinical diagnosis of lo-
calized disease but actually had undetected regional stage
disease. Hence, cases of local and regional stage disease
were combined in the present study.
Conclusion
LDS men compared with nonLDS men may have adopted
digital rectal and PSA screening more readily. Higher PSA
screening was observed among LDS, both overall and
within selected age groups according to the 1996 Utah
Health Status Survey. In addition, individuals in the LDS
Church tend to reflect a host of characteristics (i.e., low
smoking prevalence, a high proportion married, a high
proportion medically insured, and a high level of educa-
tion) that are associated with good general health. Previ-
ous studies have indicated that these characteristics are
associated with more aggressive PSA screening and, be-
cause of the high prevalence of asymptomatic prostate
cancer in the population, subsequent prostate cancer diag-
nosis. If LDS men adopted screening more readily, we
may expect that they would have experienced higher pros-
tate cancer incidence rates. Evidence in this paper indi-
cates that the comparatively high prostate cancer
incidence rates in Utah are likely due to, at least in part,
more aggressive screening among LDS.
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